FDA extends Vemlidy approval for chronic hepatitis B to children as young as 6 years
The FDA has updated the label indication for Vemlidy 25 mg for the treatment of chronic hepatitis B virus with compensated liver disease, expanding the patient population to include children aged 6 years and older who weigh at least 25 kg. Vemlidy (tenofovir alafenamide, Gilead Sciences) — a nucleoside analog reverse transcriptase inhibitor — was previously approved for the adult